cyrilzakka/clinical-trials huggingface dataset:
Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Study of autologous immune cell therapy in combination with the luteinizing hormone releasing hormone agonists (LHRH-a) in patients with metastatic castration-resistant prostate cancer

Autologous dendritic cells (DC) are known to activate other immune cells, such as central memory T cells (Tcm cells), that are able to mount an attack against cancer cells. The purpose of this study is to evaluate the feasibility, safety and efficacy of patients' own immune cells combined with the luteinizing hormone releasing hormone agonists (LHRH-a) for treatment of metastatic castration-resistant prostate cancer.

Eligibility Criteria:
Inclusion Criteria:

* Males age ≥ 18 years；
* Subjects who understand and sign the consent form for this study；
* Metastatic， castrate resistant, histologically confirmed prostate cancer；
* PSA\> 5ng / ml；
* Serum testosterone ≤ 17nmol / L (50ng / dl)；
* Expected survival time of at least 24 months；
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；
* Subjects did not receive chemotherapy, radiation therapy, surgery and other treatment within 4 weeks；

Exclusion Criteria:

* The subject has an allergic history of medicine or food；
* The patient with more serious heart disease, including but not limited to myocardial infarction, cardiomyopathy, valvular disease, malignant arrhythmia；
* Hb \<9.0 g / 100ml, WBC \<3 ×10\^9/ L, LY \<1.0 x10\^9/ L, platelet \<100,000 / mm3；
* Patients with immune disease or auto-immune disease (such as Multiple sclerosis, systemic lupus erythematosus，rheumatoid arthritis and inflammatory bowel disease, vitiligo )；
* The subject has uncontrolled or hard-to-control diseases of liver, or kidney system；
* Patient with visceral metastases, pathological fractures, spinal cord compression symptoms；
* Severe pain associated with bone metastases (VAS score ≧ 4 points)；
* Patient has received immunotherapy (including but not limited to PD-1 / PDL-1, etc.)；
* patient with irregular hemorrhagic disease；
* Subject is HIV, hepatitis B virus, hepatitis C virus, Treponema pallidum infection；
* Subject has uncontrollable seizures, or because of mental loss of self-knowledge and so on；
* The subject has an history of other malignant tumor；
* The patient had drug abuse, drug abuse, and long history of alcoholism in the 12 years prior to this trial；
* The subject has participated in any other clinical trial in the 3 months prior to this trial；
* The subject has any other unsuitable or adverse condition to be determined by the investigator.
The SUUBI Program: Asset-Ownership for Orphaned Children in Uganda

This study examines an economic empowerment model of care and support for orphaned adolescents in rural Uganda. The Suubi intervention focuses on economic empowerment of families caring for orphaned youths. It attempts to address the health risks and poor educational achievements resulting from poverty and limited options.

The AIDS epidemic and a 20-year civil war have had a devastating impact on Uganda. The events have led to population displacement, worsening living conditions, exacerbation of poverty, and disruption of already weakened social service systems. As implemented, the Suubi Project goes considerably beyond the usual care, which primarily consists of institutionalization and reactive strategies (involving food and material aid). Specifically, the intervention promotes children's savings accounts, also known as children development accounts, for postprimary education and microenterprise development (i.e., development of small income-generating businesses).

The Suubi intervention is grounded in asset theory (Sherraden 1990, 1991), which holds that assets (e.g., savings, educational opportunities, and economic opportunities in the form of income-generating activities or microenterprises) have important economic, social, and psychological benefits for individuals and families. Asset building is increasingly viewed as a critical factor for reducing poverty, improving psychosocial functioning, and positively affecting attitudes and behaviors.

Eligibility Criteria:
Inclusion Criteria:

* an orphaned child, defined as a child who has lost one or both parents to HIV/AIDS; enrolled in primary school (even though possibly not attending regularly); between the ages of 12 to 15 years.
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases

The main purpose of this study is to determine if high doses of radiation using proton beam can be given safely with low and acceptable side effects. We will also gather information to determine the ability of proton beam to destroy cancer cells in the liver. There are two types of external radiation treatments (proton beam and photon beam). Proton beam radiation is a very accurate kind of treatment that has been shown to affect less normal tissue than a regular radiation beam. The accuracy allows us to more safely increase the amount of radiation delivered to eliminate cancer and may potentially reduce the side effects normally experienced with standard radiation therapy.

* Participants will receive treatment as an outpatient at the Northeast Proton Treatment Center located at the Massachusetts General Hospital.
* Since we are looking for the highest dose of proton beam radiation that can be given to people safely, not everyone who participates in this study will be receiving the same amount of radiation. Small groups of people will be enrolled and given a certain dose of radiation. If they tolerate it well, the next small group of people enrolled will receive a higher dose. This will continue until we find the highest dose that can be given without causing serious or unmanageable side effects.
* Radiation treatment to the liver will be given once a day, 5 days a week (Monday-Friday), for 3 weeks. Each treatment takes about 10-20 minutes.
* A physical examination, medical history, and blood tests will be taken once a week for 3 weeks during radiation therapy. Follow-up visits will occur every 3 months for 2 years, and every 6 months thereafter for 3 years, and then annually thereafter.

Eligibility Criteria:
Inclusion Criteria:

* Biopsy proven unresectable or locally recurrent hepatocellular cancer, cholangiocarcinoma, or hepatic metastases.
* Primary lesion size of 6cm or less in greatest diameter
* Single or multinodular tumors (up to 3)
* 18 years of age or older
* No evidence of extrahepatic tumor
* Karnofsky performance status of 70-100
* If patient has underlying cirrhosis, only Child's classification Group A or Group B
* Adequate renal function
* Expected survival of greater than three months

Exclusion Criteria:

* Pregnant or lactating women
* Evidence of non-hepatic metastatic disease
* Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc.
* Prior radiation treatment to affected region
* Serious psychiatric illness which would limit compliance with treatment
ProLOVE - Prospective Randomized Study of Midline Incisional Hernia Treatment

This purpose of this study is to compare the recovery after an operation of an incisional hernia within the limits of the rectus muscles of the abdominal wall. The use of a mesh in the repair of a postoperative hernia is considered obligatory. Placement of a retromuscular mesh is done by open or laparoscopic surgery. Focus is on the recovery phase assuming a less painful recovery after a laparoscopic procedure.

Incisional ventral hernia after abdominal surgery is a fairly common condition. In recent years the use of a prosthesis in the repair procedure has proved very effective in preventing a new hernia. A retromuscular mesh placement seems to have superior results. The mesh may be placed retromuscular through an open surgical procedure or through a laparoscopic procedure in an intra-abdominal position. Both procedures are highly standardized. A heavy weight mesh is used in the open procedure, fixed in the midline only, and a composite mesh is used intraabdominally and fixed only with titanium tackers.

SF-36 is used to assess the quality of life, and its subscale BP (bodily pain) is used as primary outcome 3 weeks postoperatively. Secondary endpoints are return to daily life, pain, complications, recurrence, patient satisfaction and cosmetic outcome.

Subjects are assessed at 1,3,8 weeks post operation and after 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Age over 18 years
* Postoperative hernias in the region of the recti abdomini muscles with a defect of less than 10 cm transversal width
* No contraindications to laparoscopic procedure
* The patient should be able to adequate ventilation/respiration after reduction of hernia contents
* Indications for elective surgery

Exclusion Criteria:

* Pregnant women
* Prior operation of abdominal hernia with mesh placement in the compartment of the rectus abdominus muscle (i.e. prior onlay mesh is acceptable)
* Need of an interpreter
* Current drug abuse, mental disorder or other condition which makes the patient incapable of postoperative follow up
* Body Mass index (BMI) \>40
* Other planned concurrent operation
* Current oral steroid treatment, or other immune system modulating treatment
* Incarcerated incisional hernias
* Parastomal hernias
* Prior history of open abdomen
* Enterocutaneous fistula or cutaneous infection
* Hepatic cirrhosis or ascites
* Generalized malignancy
* History of radiation treatment in the abdomen.
* ASA \>III
Status Asthmaticus on the Intensive Care Prospective - STATIC PRO

This study will prospectively assess the impact and relevance of several risk factors for children with severe acute asthma (SAA) or acute wheeze that have been identified in retrospective studies. Secondary we will assess short-term medical and psychosocial functioning in patient (and parents) admitted to a PICU for SAA/acute wheeze versus a control group admitted to a MC for SAA/acute wheeze.


Eligibility Criteria:
Inclusion Criteria:

* Between 2 and 18 years of age
* Admission to a PICU for SAA or acute wheeze or admission to a MC for SAA or acute wheeze

Exclusion Criteria:

* Patient is outside of specified age range
* Down's Syndrome
* Congenital/acquired heart defect that interferes with normal SAA treatment
* Congenital/acquired airway defect (tracheomalacia/bronchomalacia)
* Primary/secondary immunodeficiency
* Pre-existing chronic pulmonary condition, known to mimic asthma: Cystic Fibrosis, Bronchopulmonary dysplasia, Bronchiolitis obliterans
* If both parents are not able to speak the Dutch language
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells

To study the effect and saftey of intratracheal instillation of mesenchymal stem cells for treatment BPD

This is a Phase 1 clinical trial that constitues two points cohorts with 100 participants per cohort who will receive instillation dose of mesenchymal stem cells-25 million cells/kg,with ventilation after 14 days.And the placebol will be 0.9% sodium choride. The investigator will proceed the groups during the same period.

1. Deographic Data and Baseline charateristics of the studied groups were collected:

   Gestational age (weeks) Birth weight (g) gender Cesarean section delivery Antenatal steroids Prolonged rupture of membrane Multiple pregnancies APGAR score at 5 minutes
2. mesenchymal stem cels dose is 25 million cells/kg
3. Assessment the incidence of BPD after instillation of Mesenchymal stem cells
4. the adverse after instillation of Mesenchymal stem cells

Eligibility Criteria:
Inclusion Criteria:

twenty-eight weeks to thirty-seven weeks prematures who need ventilaton for 14 days after birth, and the oxygen concentration is more than 30%

Exclusion Criteria:

Preterm infants with major congenital malformations, chromosomal anomalies, inborn errors of metabolism and clinical or laboratory evidence of a congenital infection
Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate

The purpose of this study is to determine the feasibility and late toxicity of dose escalated radiation therapy to the pelvic lymph nodes and prostate and seminal vesicles in the treatment of high risk prostate cancer. All eligible patients with high risk prostate cancer who are going to have primary radiation therapy to the pelvic lymph nodes and prostate seminal vesicles with or without concurrent hormonal therapy will be approached regarding study entry.

Prostate cancer is now the most commonly diagnosed cancer in Canadian men and is the third most common cause of cancer death.1 Locally advanced prostate cancer (clinical T3/T4) is uncommon in North America because of earlier diagnosis following widespread PSA testing and patient information campaigns. However, in the past decade the term high-risk prostate cancer has been developed to include the previous locally advanced disease and patient with T1/T2 disease with poor prognostic features (either a high Prostate Specific Antigen or high Gleason score). The risk of involvement of pelvic lymph nodes by prostate cancer for certain subgroups of intermediate risk and most high risk prostate cancer may be substantial. The long term results of conventional dose (66-70 Gy) external beam radiation therapy for intermediate and locally advanced prostate cancer have been disappointing. The combination of hormonal therapy and radiation therapy or radiation therapy dose escalation are the two strategies which have been evaluated and are now used to improve these results.

Eligibility Criteria:
Inclusion Criteria:

* A histologic diagnosis of adenocarcinoma of the prostate within six months of entry.
* Clinical Stage T1-T2 with (PSA \>20 or Gleason score \>7)
* Clinical Stage T3, T4
* Bone scan reported as negative for metastases within 6 months of study entry.
* All patients must have a CT scan of the abdomen and pelvis reported as negative for nodal metastases within 12 wks of study entry.
* The patient must not have received greater than 6 months of hormonal therapy.
* The patient must not have received cytotoxic anticancer therapy prior to study entry.
* Patients must have an ECOG performance status of 2 or less.
* Age 80 years old or less
* Signed informed consent

Exclusion Criteria:

* Patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy
* Patients with prior colorectal surgery
* Patients with prior or active malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer
Early Treatment Based Neuroscience Education in Knee

Determine the effecttiveness of a cross-education strength training protocol in a group of subjects with an anterior cruciate ligament surgery.

The cross-education (CE) phenomenon has been studied in recent years as a form of gain muscle strength not only in healthy subjects but also in acute injuries such as musculoskeletal disorders and immovilitations. Unilateral training of the not injured limb has been suggested as an option to produce cross-edutation in terms of strength and skills. In addition, functional magnetic resonance imaging have been postulated as a promising tool to study the mechanisms of transfer.

In the context of our study, arthrogenic muscle inhibition (AMI) of knee extensors is a common consequence after ACL repair in which a CE strength training can lead to reduce quadriceps atrophy and its implications in long terms achievements. Thus, an unilateral strength protocol of the uninjuried limb, according to the last Delphi Consensus, will be run for 8 weeks to check the possible benefits of the transfer in a sample of ACL repair.

Eligibility Criteria:
Inclusion Criteria:

* People between 18 and 40 years whith MRI diagnosis of ACL rupture.
* Autograft, allograft or artificail graft of any source.
* With/without any meniscal resection/repair.

Exclusion Criteria:

* Diagnosis of systematic disease, no injury or symptomatic in contralateral lower limb, pregnancy, current or prior neurologic condiction.
Real-time Optimized Biofeedback Utilizing Sport Techniques

This study will identify the most optimal, focused approach for biofeedback in adolescent females at high risk for anterior cruciate ligament (ACL) injury. A six-week randomized, pre/post-testing design will be used to identify biofeedback training effects. The investigators will also determine the effects of hip strategy on retention of decreased knee abduction load with focused biofeedback. A six-month follow-up design will be used to test retention of real-time biofeedback intervention.

Real-time Optimized Biofeedback Utilizing Sport Techniques (ROBUST) represents an innovative new approach to reduce traumatic anterior cruciate ligament (ACL) injuries. Over the last four decades, these debilitating injuries have occurred at a 2 to 10-fold greater rate in female compared to male athletes with the highest prevalence occurring between the ages of 16-18 years. As a consequence, there is a large population of females that endure significant pain, functional limitations and knee osteoarthritis (OA) as early as 5 years after the initial unintentional injury. To reduce the burden of OA, The National Public Health Agenda for Osteoarthritis recommends both expanding and refining evidence-based prevention of ACL injury. There currently is a gap in knowledge regarding how to maximize the effectiveness of injury prevention training in young female athletes. The long-term goal is to reduce ACL injuries in young female athletes. The objective of this application is to increase the efficacy of biofeedback training to reduce the risk of ACL injury. This proposal tests the central hypothesis that biofeedback methodology is needed to maximize the effectiveness of neuromuscular prophylactic interventions. The rationale supporting this proposal is that once the proposed research is completed, health professionals will be more successful at preventing devastating ACL injuries through properly optimized and targeted biofeedback training for young at-risk females. This research is innovative because it represents a new and substantive departure from the status quo by recognizing the need to optimize the application of biofeedback training. The work will contribute clinically relevant data in support of a future more robust clinical trial. The proposed research will be significant because it will lead to reduced rates of ACL injury in young females. Reduction of female injury rates to equal that of males would allow females annually to continue the health benefits of sports participation and avoid the long-term complications of osteoarthritis, which occurs with a 10 to 100-fold greater incidence in ACL-injured than in uninjured athletes.

Eligibility Criteria:
Inclusion Criteria:

* Currently participating on club or school sponsored soccer team

Exclusion Criteria:

* Current injury that limits participating in sport
* Male
* Cannot participate in a 6-week intervention due to time or other constraints
Effect of Occlusal Reduction on Post-operative Pain

effect of occlusal reduction on post-operative pain is evaluated after single visit root canal treatment in upper and lower molar teeth in patients with sypmtomatic irreversible pulpitis and apical periondontis


Eligibility Criteria:
Inclusion Criteria:

1. Patient's age between 20-50 years with no sex predilection.
2. Medically free patients.
3. Patients suffering from symptomatic irreversible pulpitis with symptomatic apical periodontitis in maxillary and mandibular molars with:

   * Preoperative pain.
   * Vital pulp.
   * Sensitivity to percussion.
   * Occlusal contact with the opposing teeth.
   * Normal periapical radiographic appearance or slight widening in the periodontal membrane space.

Exclusion Criteria:

1. Pregnant females.
2. Patients having a significant systemic disorder.
3. Patients who had administered analgesics or antibiotics during the last 12 hours preoperatively.
4. Patients having bruxism or clenching.
5. Teeth having :

   * No occlusal contact.
   * No sensitivity to percussion.
   * Association with swelling or fistulous tract.
   * Acute or chronic peri-apical abscess.
   * Greater than grade I mobility.
   * Pocket depth greater than 5mm.
   * No possible restorability.
   * Previous endodontic treatment
Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs

The Charcot syndrome Marie Tooth is the most frequent hereditary neuromuscular diseases: there is no curative treatment at present, on the other hand precautionary measures can be taken (physiotherapy, port of splints, orthopaedic surgery and technical assistants). In the literature and in our recent study (evaluation of the pain in the disease of CMT - Reference center of the neuromuscular diseases - CHU Bow) the frequency of the pain is important varying from 66 to 96 % cases, affecting especially hands and lower limbs. The care of the pain in the Charcot syndrome Marie Tooth is not codified. The transcutaneous neurostimulation(TENS) is a not medicinal and not invasive therapeutics, without any brought back collateral effect, used at the same time in the chronic pain and acute since 1960, as well for the neuropathic pains that musculo-scrawny. No study was realized this day on the use of the TENS with analgesic aim in the CMT. We suggest studying the analgesic efficiency of the TENS in the Charcot syndrome Marie Tooth on the pains of lower limbs, the most frequent painful location in our recent works.

The main objective will be to analyze the improvement of the pain of lower limbs, based on the decrease of the analogical visual scale(ladder) (EVA), at least 30 %.

The secondary objectives will be to estimate repercussions on the functional capacities ( ONLS), the quality of life (SF(sci-fi) 12), the satisfaction (EVA), the global impression(printing) of change ( PGIC), the consumption of analgesic, DN4, NPSI (Neuropathic Pain Symptom Inventory), Concise Questionnaire of the Pains ( QCD), HAD (Hospital Anxiety and Depression scale).


Eligibility Criteria:
Inclusion Criteria:

* Age included between 18 and 75 years
* Affected by CMT confirmed on clinical, family criteria, electrophysiological and / or genetics
* pain ≥ 3 months
* EVA pain ≥ 4/10
* patient having given his written consent and lit(enlightened)
* patient susceptible to be followed regularly during at least 3 months
* Patient member to the Social Security

Exclusion Criteria:

* Expanding patients of associated neurological pathology
* Patients having resorted to the TENS in the last 3 months
* Medical history of cancers, collagen and quite other pathology which can interfere with the experimental procedure
* Patient carrier of a pacemaker or an active implantable medical device
* Cutaneous hurt on the territory to be stimulated
* Venous or arterial thrombosis or thrombophlebitis in the territory to be stimulated
* Patient participant in another biomedical research on the pain or the period of exclusion of which in a study is not ended
* Patient under guardianship or deprived of all his liberties